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Abstract:  Numerous human genetic and acquired diseases could be corrected or 
ameliorated if viruses are harnessed to safely and effectively deliver therapeutic genes to 
diseased cells and tissues in vivo. Innate immune and inflammatory response represents 
one of the key stumbling blocks during the development of viral-based therapies. In this 
review, current data on the early innate immune responses to viruses and to the most 
commonly used gene therapy vectors (using adenovirus and adeno-associated virus) will 
be discussed. Recent findings in the field may help develop new approaches to moderate 
these innate immune anti-viral responses and thus improve the safety of viral vectors for 
human gene therapy applications.  
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1. Introduction  
During the millions of years of co-evolution, viral pathogens and their hosts evolved to an 
equilibrium allowing both hosts and viruses to coexist and thus survive. However, this equilibrium is 
quasi-stationary due to constant adaptation of viruses to existing or new hosts and to eternal selection 
within these hosts for the most effective antiviral mechanisms. One of the best testaments to the quasi-
stationary nature of the balance between viruses and their hosts is a set of recent reports of 
unanticipated severe innate immune and inflammatory responses to rather benign viral pathogens used 
as gene delivery vehicles in human gene therapy trials [1-3]. Viruses are obligate pathogens and are 
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very efficient at infecting host cells that support their reproduction and dissemination. Clinical studies 
suggest that, in many cases, a small number of virus particles is sufficient to transmit virus-associated 
disease [4]. Moreover, viruses develop an array of factors and strategies that allow them to evade or 
modulate the host immune system. These factors facilitate rapid completion of the viral reproductive 
cycle, contributing to the spread of infection. In response to the ever-present threat from viruses, hosts 
have evolved molecular mechanisms to detect virus infection and limit virus-induced damage. 
Abundant information has recently emerged on the molecular mechanism of innate immunity to virus 
infection in mammals [5]. One of the fundamental principles of virus recognition by the host innate 
immune system appears to rely on the sensing of virus-associated nucleic acids in infected cells by 
specialized classes of receptors – Toll-like receptors (TLRs), retinoid acid-inducible gene I (RIG-I)-
like receptors (RLRs), and nucleotide oligomerization domain (NOD)-like receptors (NLRs) (Figure 
1). This latest evidence also indicates that the host recognition of cell damage or stress induced merely 
by virus entry into cells is likely to be the second key principle for virus sensing which does not rely 
on pathogen-associated nucleic acid recognition.  
2. Molecular Basis for Cellular Recognition of Virus Infection 
The obligate nature of viral pathogens creates a considerable challenge for the host to detect onset 
and continuation of virus infection. Because viruses replicate in host cells and frequently utilize host 
protein and nucleic acid processing machineries, host/non-host discrimination becomes complicated 
based solely on pathogen-specific chemical moiety recognition. However, the natural diversity of   
virus-associated nucleic acids makes them a legitimate target for detection within infected cells. While 
mammalian cells under normal physiologic conditions possess only a limited number of nucleic acid 
types, such as double-stranded (ds) DNA with methylated CpG motifs and single-stranded (ss) RNA 
with a cap structure at the 5’ end of the molecule, the structure of virus-associated nucleic acids is very 
diverse. Viruses encode their genetic information in a form of ssDNA, linear dsDNA, circular dsDNA, 
ssRNA, dsRNA, all with myriads of unique modifications and permutations of polarity and replicative 
intermediates. Accumulating evidence suggests that host recognition of virus-associated nucleic acids 
is a fundamental principle for sensing virus infection in mammalian cells. 
2.1. TLR-dependent recognition of virus infection 
One of the best-studied families of receptors mediating pathogen recognition by the innate immune 
system are TLRs. There are more than 10 distinct TLR receptors identified in mammals to date [6]. 
TLR3, TLR7, and TLR9 were shown to recognize viral-associated nucleic acids in the cellular 
endosomal compartment. TLR3 is activated by a dsRNA [7], TLR7 is activated by a ssRNA [8-10], 
and TLR9 is activated by an unmethylated CpG DNA motif [11]. While TLR3 is expressed in many 
cell types, TLR7 and TLR9 are expressed at high levels in plasmacytoid dendritic cells (pDCs) [12]. 
All TLR-initiated signaling converges on the activation of type I interferon (IFN-I) through the 
engagement of IRF3 and/or IRF7 transcription factors and the early response inflammatory cytokine 
genes via activation of NF-B [13] (Figure 1). Despite this convergence on a specific set of genes, the 
signaling pathways that lead to IFN-I and cytokine gene activation in response to TLR engagement are 
cell-type specific and recruit different adaptors and mediators depending on the type of TLR. dsRNA Viruses 2010, 2                                       
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binding to TLR3 ecto-domain in the endosomes leads to receptor dimerization and the recruitment of 
an adaptor molecule TRIF (also known as TICAM-1) [1416]. TRIF then binds TRAF3 and TRAF6 
proteins via TRAF-binding motifs that are present within N-terminal region of TRIF [17]. TRAF6 is 
responsible for activating NF-B that leads to the expression of pro-inflammatory cytokines [18]. 
TRIF, however, can also activate TBK1 and IKKi protein kinases, which phosphorylate IRF3 and lead 
to its translocation into the nucleus and activation of IFN-I [19,20]. TLR3 plays critical role in 
controlling replication of MCMV in mice as well as purified reovirus genomic dsRNA is a potent 
activator of IFN-I in a TLR3-dependent manner [7,21].  
Figure 1. Three classes of pattern recognition receptors engaged in sensing viral nucleic 
acids in infected cells. See text for the detail description of their respective structures, 
ligand specificities, and roles in inducing host antiviral responses. 
 
 
In the cellular endosomal compartment, TLR7 and TLR9 recognize ssRNA and unmethylated CpG 
DNA, respectively [8-11]. Upon engagement of a cognate ligand, TLR7 and TLR9 initiate signaling 
through a common adaptor molecule myeloid differentiation factor 88 (MyD88) [22]. MyD88 then 
interacts with IL-1R-associated kinase 4 (IRAK-4) [5]. IRAK-4, in turn, transduces the signal though 
IRAK-1 and IRAK-2, that leads to the activation of TRAF6. Activation of TRAF6, through a set of 
protein kinases, results in phosphorylation of mitogen activated protein kinase 6 (MAPK6) and IKK-, 
which modulate the activation of NF-B and MAPKs leading to the production of pro-inflammatory 
cytokines. In pDCs, activation of TLR7 and TLR9, in addition to inflammatory cytokine production, 
leads to a MyD88-dependent activation of IRF7 which is responsible for the induction of IFN-I 
[23,24]. In pDCs, vesicular stomatitis virus (VSV) RNA is recognized by TLR7 upon autophagosome 
formation [25]. In response to adenovirus infection, pDCs in vitro activate IFN-I production in a TLR-
9-dependent manner [26]. Viruses 2010, 2                                       
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2.2. RLR-dependent recognition of virus infection 
Upon entry into host cells, many viral pathogens (specifically those with lipid envelopes such as 
influenza and human immunodeficiency virus [HIV]) avoid exposure of their genomic nucleic acids to 
endosomal TLRs. However, activation of IFN-I in response to virus infection is afforded through a 
cytoplasmic detection of viral RNAs by an RLR family of receptors, consisting of RIG-I and 
melanoma differentiation-associated gene 5 (MDA5) [27-29]. RIG-I and MDA5 directly bind viral 
RNA via the helicase domain [30] (Figure 1). Although both RIG-I and MDA-5 can bind dsRNA, 
MDA-5 activates IFN-I production upon binding of long (>2kb, dsRNA species [31]) while RIG-I 
induces IFN-I upon binding of short dsRNA and 5’-triphosphate-containing ssRNA [32-34]. Similarly 
to the TLR receptor family, IFN-I and inflammatory cytokine genes are the principal targets of RLR 
receptors’ signaling. When the viral RNA binds to and activates RIG-I or MDA5, these proteins 
engage key adapter protein IFN- promoter stimulator-1 (IPS-1), also known as mitochondrial 
antiviral (MAVS), virus-induced signaling adapter (VISA), or CARD adapter inducing IFN- 
(CARDIFF) [35-38]. Activated IPS-1 recruits TNFR-associated death domain protein (TRADD) 
which forms a complex with TRAF3 and receptor-interacting protein RIP-1 [39]. TRAF3 is critical for 
IFN-I induction and mediates activation of TBK1 and IKKi kinases which phosphorylate IRF3 and 
IRF7, leading to activation of IFN-I and a set of IFN-I-inducible genes [20,40]. IPS-1 also is critical 
for the activation of inflammatory cytokine genes mediated by NF-B via phosphorylation of classical 
IKK/ kinases.  
MDA-5 and RIG-I are important for activating host responses to RNA viruses. RIG-I was shown to 
activate IFN-I in response to paramyxoviruses, VSV, influenza virus, hepatitis C virus, and Japanese 
encephalitis virus infection [41-44]. MDA5 is critical for IFN-I production in response to reoviruses 
[31] and picornaviruses, including encephalomyocarditis virus (ECMV) and Theiler’s virus [45]. Mice 
that lack both MDA5 and RIG-I are highly susceptible to VSV and EMCV virus infection [5,29]. 
Collectively, cytoplasmic detection of viral RNAs by RLR appears to be the key pathway of host 
innate immunity activation by RNA viral pathogens. 
2.3. NLR-dependent recognition of virus infection 
NLR family consists of a relatively large number of intracellular receptors with a prototypic 
tripartite structure [46,47]. The N-terminus is composed of either a caspase recruitment domain 
(CARD) or a Pyrin domain (PYD) that are important for signal transduction. The central part of the 
NLR molecule is composed of a nucleotide-binding domain (NBD) critical for ATP binding and 
oligomerization. The C-terminus is composed of a leucine-rich repeat (LRR) domain, important for 
ligand binding and autoregulation of the NLR function [48]. Upon engagement of a LRR-specific 
ligand, NBD binds ATP, leading to oligomerization of the NLR and initiation of a signal transduction 
via N-terminal domain binding specific adaptors, then leads to the activation of MAPK kinases and 
NF-B (in case of a PYD N-terminal domain), or association of NLR with a supramolecular complex 
of proteins called “inflammasome” via CARD domain [49]. In addition to an NLR, inflammasome 
includes ASC adapter protein and inflammatory caspases, such as caspase-1 [50] (Figure 1). Upon 
activation of NLR and its recruitment into the inflammasome complex, pro-caspase-1 is processed into Viruses 2010, 2                                       
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functionally active caspase-1, which further cleaves pre-IL-1 into mature IL-1, leading to its release 
from cells and activation of the IL-1R signaling pathway. 
There is abundant evidence demonstrating the essential role of NLRs in sensing and controlling 
microbial infection in mammalian cells [51]. Regarding the NLR involvement in recognition of viral 
infection, recent data indicate that the NLR family member NLRP3 (also called Cryopyrin) plays an 
essential role in sensing viral and microbial DNA in macrophages in vitro [52]. Recent data also 
suggest that NLRP3 mediates recognition of influenza A virus infection [53,54]. Mice deficient for 
NLRP3 exhibit dramatically increased mortality and reduced immune response to the influenza virus. 
NLRP3 inflammasome activation by influenza virus was dependent on lysosomal maturation and 
reactive oxygen species. It was also suggested that NLRP3 inflammasome is involved in sensing viral 
RNA [53], while another study also implicates NLRP3 inflammasome in the resolution of 
inflammation [54]. 
2.4. Recognition of cytoplasmic dsDNA by DAI and AIM2 
Intra-cytoplasmic detection of dsDNA represents an important mechanism for the detection of viral 
and microbial pathogens. Although several studies clearly showed that cells transfected with dsDNA 
leads to activation of IFN-I and NF-B-dependent inflammatory cytokines, the molecular sensors of 
dsDNA in the cytoplasm that remained unidentified until recently. Takaoka et al. showed that dsDNA-
dependent activation of IFN-I production in cells is mediated by a protein named DNA-dependent 
activator of IFN-regulatory factors (DAI) [55]. DAI was also known as Z-DNA binding protein ZBP-1 
and DLM-1 and was shown to directly bind dsDNA via its Z and Z DNA binding domains that are 
homologous to the nucleic acid binding domain adenosine deaminase acting on RNase1 (ADAR1) of 
an RNA-editing protein. Although DAI binds left-handed Z-form DNA with high affinity, it also binds 
B-form DNA and activates phosphorylation of IRF3 via TBK-1 serine/threonine kinase [56]. 
Inhibition of DAI using siRNA reduced activation of IFN-I production in response to human 
herpesvirus 1 (HSV-1), suggesting its potential role in detecting and mounting innate immune 
responses to DNA viruses.  
Most recently, four groups independently reported the identification of a protein absent in 
melanoma 2 (AIM2) as a specific sensor of dsDNA in the cytoplasm [57-60]. AIM2 binds dsDNA via 
its C-terminal HIN-200 (hematopoietic interferon-inducible nuclear proteins with a 200–amino acid 
repeat) domain and this binding leads to oligomerization of the protein [61]. The N-terminal PYD 
domain of oligomerized AIM2 is capable of recruiting both ASC and caspase-1 inflammasome 
components and drives the activation of caspase-1 that then leads to IL-1 pre-protein processing and 
release of mature IL-1.  Knockdown of Aim2 abrogates caspase-1 activation in response to 
cytoplasmic dsDNA and the dsDNA vaccinia virus in vitro. However, AIM2 appears to not be 
normally present in the cytoplasm of uninfected cells and its expression depends on cell stimulation 
with IFN-I. This data suggests that, although AIM2 is critical for activation of inflammasome by 
dsDNA, it is unlikely to play a role in early recognition of viral infection. Instead, early stages of virus 
infection may activate IFN-I, which in turn leads to AIM2 expression that assists executing phases of 
innate immunity activation, such as processing and release of pre-synthesized IL-1, if dsDNA is 
present in the cytoplasm.  Viruses 2010, 2                                       
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3. Specifics of Innate Host Responses to Viral Gene Therapy Vectors 
The existence of an array of specific receptors enabling detection of viruses within the cell is 
counterbalanced by numerous evasion strategies and mechanisms developed by virus pathogens. For 
instance, hepatitis C virus (HCV) encodes protein NS3/4A that cleaves IPS-1 and thus prevents IFN-I 
induction upon virus infection [62,63]. The packaging of viral genomic nucleic acids in association 
with virus-encoded DNA- or RNA-binding proteins may also represent a strategy to avoid detection of 
viral genomes in infected cells by TLRs, NLRs, or RLRs.  
To achieve the goal of correcting human diseases, viral vectors for gene therapy must be able to 
safely and effectively deliver therapeutic genes to disease sites. However, the incorporation of 
therapeutic genes, along with all the necessary regulatory elements to guide tissue-specific transgene 
expression, often requires deletion of viral genes that are dispensable for vector production. Moreover, 
many viral vectors are based on attenuated forms of viruses that were specifically modified to reduce 
their virulence and prevent the re-emergence of their fully virulent forms. Most frequently such 
modifications of viruses are made at the expense of viral genes that counteract host innate and adaptive 
immunity. This makes viral vectors more prone to induce strong innate and/or adaptive immune 
responses. Another important consideration that may play a role in the induction of potent innate 
immune and inflammatory responses to viral vectors is that drastically higher doses of virus particles 
are delivered in vivo for therapeutic gene transfer, compared to doses that initiate natural virus 
infection. Indeed, a handful of wild type adenovirus particles are sufficient to induce a respiratory 
disease but in gene therapy trials adenovirus vectors may be delivered either locally or systemically at 
a single bolus dose of >10x10
12 virus particles [1]. Clearly, the exposure of host cells to such a 
massive number of virus particles could initiate host responses that may be vastly distinct in magnitude 
and severity compared to those observed upon natural virus infection. One of the currently emerging 
concepts implies that due to the high vector doses that are needed to achieve efficient gene transfer and 
therapeutic gene expression, the activation of innate immunity to gene therapy vectors occurs due to 
the engagement of mechanisms that are naturally responsible for the detection of host cell damage or 
stress.  
4. Innate Responses to Adenovirus Vectors 
Adenovirus vectors (Ads) are the second most frequently used vectors in clinical trials in the US to 
treat numerous inborn and acquired human diseases, including cystic fibrosis and cancer [64]. Interest 
in Ad has recently increased considerably due to its potential as a vector for vaccination against life 
threatening infectious agents including anthrax [65,66]. Many of these potential applications will 
ultimately require intravenous Ad administration to achieve the desired therapeutic goals. Since a 
patient tragically died due to disseminated intravascular coagulation, systemic inflammation and 
multiple organ failure after Ad administration via the hepatic artery during a gene therapy trial in 1999 
[3], major concerns have risen regarding the safety of systemic Ad injection. A decade later, the 
mechanistic aspects of and molecular pathways involved in triggering acute anti-Ad inflammatory 
response still remain poorly defined. Recent studies  strongly suggest that the immediate innate 
immune response towards intravenously delivered Ads consists of several discrete components and Viruses 2010, 2                                       
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include cytokine activation, pro-inflammatory M death, and influx of inflammatory leukocytes into 
affected sites.  
4.1. Molecular mediators of early innate immune responses to Ad vectors 
Even though natural infections with Ads are largely harmless in humans, an intravenous Ad vector 
administration for gene delivery purposes, especially at high doses, stimulates strong innate and 
adaptive immune responses and can be fatal for the host [1-3,67,68]. Upon systemic application of Ads 
in rodents, rhesus monkeys, and humans, a rapid liver-mediated vector removal from circulation was 
observed [68-74]. After intravenous delivery, Ads induce two phases of inflammatory gene expression 
in the liver. The first phase of acute inflammation occurs within 24 h of virus administration, and is 
entirely dependent on virus capsid interactions with the host cells [75]. The second phase begins 3-4 
days after Ad administration and requires viral gene expression [76]. In animal models, intravenous Ad 
administration has been shown to induce transcription and release into the blood of a number of 
cytokines and chemokines, including IFN-I, IL-6, TNF-, RANTES, IP-10, IL-8, MIP-1, MIP-1 
and MIP-2 [76-82]. Macrophages, including tissue residential macrophages (e.g., Kupffer cells in the 
liver), and dendritic cells throughout the body are considered to be the primary source of these 
cytokines and chemokines following their transduction with Ads [75]. Additionally, a rapid clearance 
of Ad from circulation by Kupffer cells may have a protective role against the dissemination of Ads to 
lymphoid organs, therefore reducing systemic inflammation. In several gene therapy clinical trials, 
serum levels of IL-6, IL-10 and IL-1 were elevated [83-86] after intravenous Ad administration at high 
doses (2x10
12 – 6x10
13 virus particles). The role of these cytokines in the initiation of an immediate 
innate immune response remains unclear. Histological evaluation of tissues, including lung, liver, and 
spleen, revealed areas of leukocyte and neutrophil infiltration as well as infarcts ([79,87], and our 
unpublished observation), indicating that most tissues in the body are involved in the inflammatory 
response to Ad after intravenous virus injection. It has been widely accepted that Ad-mediated liver 
damage plays a central role in the pathogenesis of acute systemic inflammation caused by intravenous 
Ad administration. To this end, it has been found that the activation of MIP-2 chemokine is at least 
partially responsible for neutrophil attraction to liver tissue, and that inactivation of MIP-2 with an 
anti-MIP-2 antibody ameliorates liver pathology after intravenous Ad administration [79]. To date, 
accumulating evidence suggests that Ad triggers highly complex multifaceted innate immune and 
inflammatory responses, which are reflected at a clinical level in cytokinemia, thrombocytopenia, 
complement activation, disseminated intravascular coagulation, and multiple organ failure due to (at 
least in part) collateral damage from infiltrating pro-inflammatory leukocytes. Despite considerable 
recent progress in defining early mediators of Ad-induced inflammation [26,52,88-90], the unifying 
mechanistic description of the sequential events that lead from early Ad-host cell interactions to 
clinical signs of Ad-triggered systemic toxicity remains illusive. 
4.2. Molecular sensors of Ad infection 
Using microarray technology, it was found that adenovirus infection rapidly dysregulates 
expression of up to 15% of all mRNA transcripts in mouse liver tissue or in human epithelial A549 
cells [91,92]. These data prompted the search for intracellular sensor molecules that might be involved Viruses 2010, 2                                       
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in recognition of adenovirus capsid components that can be collectively called molecular sensors of 
adenovirus infection.  
From earlier studies it was established that the expression of genes involved in innate immune and 
inflammatory responses was significantly up-regulated shortly after Ad vector delivery, but prior to 
initiation of viral gene expression. In mouse and non-human primate models, Wilson and co-workers 
demonstrated activation of innate responses by transcriptionally-defective adenovirus particles   
[77,78]. Consistent with these findings, severe acute inflammatory response was also observed in a 
non-human primate model after the intravenous delivery of a helper-dependent Ad vector which 
lacked all viral genes [1]. These data directly demonstrate that the dose-dependent activation of innate 
immune and inflammatory responses are primarily mediated by adenovirus particle interaction with 
host cells and do not require viral gene expression.  
Due to the central role of TLRs in detecting invading pathogens, considerable efforts were made to 
determine if this family of receptors is involved in the recognition of Ad infection. Recent data suggest 
that in response to Ad, plasmacytoid dendritic cells secrete type-I IFN in a TLR-9-dependent manner 
[93,94]. It is of interest that human cell lines expressing TLR9, permissive to infection by both 
coxsackievirus and adenovirus receptor (CAR)- and CD46-interacting Ad serotypes, showed a 
preferential activation of TLR9-mediated signaling by CD46-interacting serotypes [93]. These data are 
consistent with earlier findings that CD46-interacting Ads select an alternate intracellular trafficking 
pathway and reside in late endosomal compartments for longer times, compared to CAR-interacting 
Ad serotypes [95]. Because TLR9 expression is localized to late endosomal compartments, it appears 
that Ad DNA may activate TLR9 and induce type-I IFN expression. Using helper-dependent Ad 
vectors, Curello et al. found that the immediate innate immune response, assessed by plasma levels of 
IL-6 and IL-12, was partially attenuated in TLR9 knockout mice, when compared to the control group 
expressing wild type levels of TLR9 [96]. The involvement of TLR-mediated pathways in the 
induction of anti-Ad host responses was further analyzed in wild type and MyD88-knockout mice. 
These studies provided evidence that IFN-I is induced in response to Ad infection both in MyD88-
dependent and -independent manner. For instance, plasmacytoid DCs produced IFN/ in a TLR9 and 
MyD88-dependent manner, however, conventional DCs and macrophages initiated IFN-I production 
through a MyD88-independent mechanism, which likely involved an as yet unidentified cytosolic 
sensor of DNA [26]. In a very thorough study by Nociari et al., the authors provide further evidence 
that IFN-I expression in response to cell infection with Ad vectors occurs in a MyD88-independent 
manner. This data supports the idea that Ad DNA is likely detected by an unidentified sensor of 
nucleic acids in the cytoplasm [89]. This group provided compelling evidence that the Ad genomic 
dsDNA can induce phosphorylation of interferon regulatory factor IRF3, which is the key transcription 
factor in activating the antiviral IFN-I mediated signaling pathway. In a more recent paper, Fejer et al. 
demonstrated that plasmocytoid DCs are the principal source of type I IFN, which is activated 2-4 
hours after intravenous Ad administration [88]. These authors also defined IRF7 as a critical mediator 
of Ad-induced IFN-I activation in vivo.  
Recently, Muruve et al. reported that the NLRP3 inflammasome recognizes cytosolic microbial and 
host DNA and triggers the activation of host innate immune responses [52]. In addition to plasmid or 
bacterial DNA, the authors used Ad to demonstrate the involvement of NLRP3 inflammasome in 
cytosolic DNA sensing. Based on data obtained using in vitro systems 6 hours after virus infection, it Viruses 2010, 2                                       
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was proposed that Ad is sensed by macrophages when virus particles reach for the cytosol and expose 
viral genomic DNA to the NLRP3 inflammasome sensor, which, via ASC, activates caspase-1 
processing, that leads to IL-1 maturation and release. However, recent data from our laboratory 
strongly argues against the critical role of NLRP3 inflammasome in sensing Ad entry into cells in vivo 
and activating innate immune and inflammatory anti-Ad responses. Using a set of mice deficient for 
critical mediators of innate immunity and inflammation, we demonstrated that macrophage-derived  
IL-1 is the principal activator of the innate immune response to Ad in vivo [97]. Activation of IL-1 
did not require MyD88-, TRIF-, or TRAF6-signaling, and occurred in mice deficient for IL-1, IFN-
IR, or inflammasome components caspase-1, ASC, and NLRP3. These findings strongly suggest that 
signaling pathways that were earlier implicated in the activation of an innate antiviral response and 
leading to IFN-I production [5] are not involved in triggering inflammatory and innate immune 
responses to Ad. Our studies also demonstrated that the IL-1-mediated response critically depends on 
viral RGD motif-mediated binding to macrophage 3 integrins, which occurs prior to the 
internalization of the virus into the cell [98,99]. However, the magnitude of inflammatory response to 
Ad was greatly amplified by the virus-mediated endosome rupture. Because IL-1 is a key mediator of 
host inflammatory responses to dying cells [100], our studies strongly suggest that host cells trigger 
the activation of innate immunity to Ads via engaging cell damage or endosomal stress response 
mechanisms, rather than via sensing genomic Ad DNA within infected cells. However, in some 
specialized cell types like pDCs, sensing of Ad DNA by TLR9 may also contribute to the induction of 
innate anti-Ad responses [26]. Considering the major progress in our understanding of Ad-host 
interactions in recent years, it is conceivable that a comprehensive model of activation of innate 
immune and inflammatory responses by Ad in vivo will emerge in the near future.  
5. Innate Responses to Adeno-Associated Virus Vectors 
To date, numerous pre-clinical and clinical studies demonstrated that viral vectors based on   
adeno-associated virus (AAV) are relatively safe when delivered via an intravenous route and do not 
induce robust innate immune and inflammatory responses [101,102]. However, the host innate immune 
system plays a central role in shaping the outcome of a gene delivery using AAV-based vector systems 
[103]. The earlier studies clearly demonstrated that when injected intravenously into mice at high 
doses, AAV induces transcriptional activation of inflammatory cytokine and chemokine genes, 
including TNF-, RANTES, MIP-1, MIP-2, MCP-1, and IP-10. Moreover, the absolute amounts of 
these cytokines and chemokines in the liver 1 hour after virus injection were comparable for AAV and 
Ads [104]. Although the expression of these genes greatly receded by 6 hours after AAV (but not Ad) 
administration, this data indicates that the AAV cell entry process and/or early interactions with host 
cells triggers the activation of signaling pathways that initiate the unraveling of a stereotypic   
pro-inflammatory host response. The same study further showed that Kupffer cells were primarily 
responsible for the activation of these pro-inflammatory genes in the liver after AAV administration 
[104].  
Because adaptive immunity represents a principal barrier for successful gene transfer using   
AAV-based vectors [103], much effort was made to understand the AAV interaction with professional 
antigen-presenting cells, specifically DCs. In a most recent and very detailed study by Zhu et al., the Viruses 2010, 2                                       
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authors found that AAV is recognized by pDCs via TLR9-MyD88-dependent pathway [105]. As noted 
above, in this specialized cell type, TLR-MyD88 pathway is coupled to IRF7 activation that leads to 
IFN-I production. Zhu et al. further demonstrated that AAV-mediated induction of IFN-I in pDCs is 
completely dependent on TLR9 and MyD88 in vitro. Importantly, they further demonstrated that 
TLR9-MyD88 pathway was critical for the activation of CD8+ T cell responses to both the transgene 
product and AAV capsid in vivo, leading to the generation of both transgene product-specific and 
AAV capsid-specific neutralizing antibodies [105]. Collectively, these data are fundamental for our 
understanding of the AAV-based vector recognition by the host cells and for the development of 
approaches to modulate the innate immune system to reduce vector recognition and improve 
therapeutic transgene expression in the target cells. 
6. Conclusions  
The wealth of new data on molecular sensors of viral infection that emerged during the last two 
years creates an opportunity for the development of basic paradigms of virus infection recognition in 
mammalian cells. One of the fundamental principles of virus-host discrimination by the innate immune 
system appears to rely on recognition of virus-associated nucleic acids by the specialized families of 
receptors TLRs, RLRs, and NLRs. While the TLR receptors function at the cell surface and within the 
cellular endosomal compartments, RLR and NLRs function within the cellular cytoplasm. Although 
the engagement of TLRs and RLRs triggers the activation of signal transduction pathways leading to 
the inflammatory cytokine and chemokine gene expression, NLRs are critical for the executive stages 
of innate immunity activation and process inflammatory caspases and inflammasome-dependent 
cytokines.  
The activation of innate immune responses to viral vectors also occurs via the engagement of TLRs 
and NLRs. However, in addition to direct detection of their genomic nucleic acids, host cells may 
recognize viral vectors though an indirect sensing of cell damage or stress that occurs due to a high 
vector dose delivery frequently employed in gene transfer protocols. Importantly, it was found that in 
response to viral vectors, different cell types activate distinct signaling pathways that ultimately shape 
the multifaceted innate immune and inflammatory responses observed in pre-clinical studies and 
clinical gene therapy trials. Future studies should focus on improving our understanding of cell   
type-specific pathways and mediators of inflammation in response to the viral vector administration in 
vivo. This information will be critical for the development of new approaches to selectively modulate 
these responses and ultimately to improve the safety of viral vector-mediated gene transfer for human 
gene therapy application.  
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